Comparative Pharmacology
Head-to-head clinical analysis: DETROL LA versus VESICARE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL LA versus VESICARE.
DETROL LA vs VESICARE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
Competitive antagonist at muscarinic acetylcholine receptors (M1-M5), with selectivity for M3 receptors over M2. Inhibits bladder detrusor muscle contraction, increasing bladder capacity and reducing urinary urgency.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
5 mg orally once daily; may increase to 10 mg once daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
Terminal elimination half-life is approximately 45 hours (range 33–57 hours), supporting once-daily dosing.
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Approximately 70% of an oral dose is excreted in urine (mainly as metabolites, <15% unchanged) and 25% in feces.
Category C
Category C
Anticholinergic
Anticholinergic